All In Biotech

Free tool

FAERS Monitor: Turalio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211810 or its brand name (Turalio, Pexidartinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

717

Serious

117

16% of reports

Hospitalization

53

Death reported

14

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue270
  • fatigue251
  • hair colour changes236
  • nausea138
  • pruritus113
  • off label use106
  • rash87
  • therapy cessation81
  • pain76
  • headache72
  • product dose omission in error69
  • product use issue67
  • diarrhoea66
  • arthralgia65
  • no adverse event56

Reports by year received

View as table
YearReports
201937
2020109
2021131
2022115
2023120
2024105
202561
202639

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,442 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hair colour changesSignal236567.0510.0130,345
product dose omission in errorSignal6971.757.24,731
therapy cessationSignal8146.437.83,553
product dose omission issueSignal27027.024.56,812
product use issueSignal6710.58.3569
fatigueSignal2519.58.61,963
no adverse eventSignal569.17.1397
pruritusSignal1138.67.3768
rashSignal875.94.8353
nauseaSignal1385.14.4470
arthralgiaSignal654.63.6182
painSignal763.62.9146
off label useSignal1063.63.0200
headacheSignal723.42.7121
diarrhoeaSignal663.02.489

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.